ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020
Aggressive multiple sclerosis (2): Treatment.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.CNS drugs · 2026Observational
- Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.Neurology and therapy · 2026Article
- Should autologous HSCT be a first-line option in highly active MS? Commentary.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Frailty Exacerbates Disability in Progressive Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).Journal of neurology · 2025Observational
- The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.Journal of neurology · 2025Article
- Multiple sclerosis: a practical review for pathologists.Journal of pathology and translational medicine · 2025Article
- Article
- Neuroimaging phenotype characterization of early aggressive and late severe multiple sclerosis: a case-control study.Brain communications · 2025Article
- Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.Journal of neurology · 2024Article
- Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.Journal of neurology · 2024Article
- Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain.PharmacoEconomics - open · 2023Article
- Are highly active and aggressive multiple sclerosis the same entity?Frontiers in neurology · 2023Article
- Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Novel Drugs in a Pipeline for Progressive Multiple Sclerosis.Journal of clinical medicine · 2022Review
- [Clinical and radiological effectiveness of natalizumab extended dosage interval in patients with relapsing multiple sclerosis].Revista de neurologia · 2022Observational
- Predictive MRI Biomarkers in MS-A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.Journal of internal medicine · 2021Review
- Iron Heterogeneity in Early Active Multiple Sclerosis Lesions.Annals of neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.